MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biogen Inc.

< Previous 1 2 3 Next >
News headline image
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB SUPN
News headline image
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB SAGE
News headline image
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story